Literature DB >> 12140762

DNA binding and 3'-5' exonuclease activity in the murine alternatively-spliced p53 protein.

Zippora Shakked1, Michael Yavnilovitch, A Joseph Kalb Gilboa, Naama Kessler, Roland Wolkowicz, Varda Rotter, Tali E Haran.   

Abstract

In this study we show that the naturally occurring C-terminally alternative spliced p53 (referred to as AS-p53) is active as a sequence-specific DNA binding protein as well as a 3'-5'-exonuclease in the presence of Mg2+ ions. The two activities are positively correlated as the sequence-specific DNA target is more efficiently degraded than a non-specific target. In contrast, a mutated AS-p53 protein that is deficient in DNA binding lacks exonuclease activity. The use of modified p53 binding sites, where the 3'-phosphate is replaced by a phosphorothioate group, enabled the inhibition of DNA degradation under the binding conditions. We demonstrate that AS-p53 interacts with its specific DNA target by two distinct binding modes: a high-affinity mode characterized by a low-mobility protein-DNA complex at the nanomolar range, and a low-affinity mode shown by a high-mobility complex at the micromolar range. Comparison of the data on the natural and the modified p53 binding sites suggests that the high-affinity mode is related to AS-p53 function as a transcription factor and that the low-affinity mode is associated with its exonuclease activity. The implications of these findings to a specific cellular role of AS-p53 are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12140762     DOI: 10.1038/sj.onc.1205667

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  DNA damage tolerance pathway involving DNA polymerase ι and the tumor suppressor p53 regulates DNA replication fork progression.

Authors:  Stephanie Hampp; Tina Kiessling; Kerstin Buechle; Sabrina F Mansilla; Jürgen Thomale; Melanie Rall; Jinwoo Ahn; Helmut Pospiech; Vanesa Gottifredi; Lisa Wiesmüller
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-12       Impact factor: 11.205

2.  Excision of nucleoside analogs from DNA by p53 protein, a potential cellular mechanism of resistance to inhibitors of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Mary Bakhanashvili; Elena Novitsky; Ethan Rubinstein; Itzchak Levy; Galia Rahav
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein.

Authors:  Jinwoo Ahn; Masha V Poyurovsky; Nicole Baptiste; Rachel Beckerman; Christine Cain; Melissa Mattia; Kristine McKinney; Jianmin Zhou; Andrew Zupnick; Vanesa Gottifredi; Carol Prives
Journal:  Cell Cycle       Date:  2009-05-15       Impact factor: 4.534

Review 4.  The Tip of an Iceberg: Replication-Associated Functions of the Tumor Suppressor p53.

Authors:  Vanesa Gottifredi; Lisa Wiesmüller
Journal:  Cancers (Basel)       Date:  2018-07-28       Impact factor: 6.639

5.  Physical and functional interactions between human mitochondrial single-stranded DNA-binding protein and tumour suppressor p53.

Authors:  Tuck Seng Wong; Sridharan Rajagopalan; Fiona M Townsley; Stefan M Freund; Miriana Petrovich; David Loakes; Alan R Fersht
Journal:  Nucleic Acids Res       Date:  2008-12-09       Impact factor: 16.971

6.  Probing potential binding modes of the p53 tetramer to DNA based on the symmetries encoded in p53 response elements.

Authors:  Buyong Ma; Arnold J Levine
Journal:  Nucleic Acids Res       Date:  2007-11-05       Impact factor: 16.971

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.